Syndesi Therapeutics

Chemin Du Cyclotron 6

1348 Ottignies-Louvain-La-Neuve

BE

Syndesi Therapeutics

Foundation date

19-12-2017

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment.

Latest news

  • Mayne Pharma and Mithra announce TGA approval of Nextstellis® oral contraceptive

    23 hours ago

  • Bone Therapeutics and Link Health sign a non-binding term sheet for the global rights of ALLOB

    23 hours ago

  • S-Biomedic announces topline results of a successful clinical study in acne

    Friday November 26th 2021